SAGE Therapeutics Stock Price. Everything You Need To Know About The SAGE Therapeutics Stock!
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 689 full-time employees. The company went IPO on 2014-07-18. The firm is focused on developing and commercializing brain health medicines. The firm’s product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD) in adults. The company has a portfolio of other product candidates with a focus on modulating two central nervous systems (CNS) receptor systems, GABA and NMDA. The company targets diseases and disorders of the brain with three focus areas: depression, neurology and neuropsychiatry. Its other advanced product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder (MDD) and PPD. Zuranolone is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. The firm has a portfolio of other compounds that target GABAA receptors, including SAGE-324.
SAGE Therapeutics Stock Price. Everything You Need To Know About The SAGE Therapeutics Stock! performance
- Employees 689
- Company HQ Cambridge
- Website https://www.sagerx.com/
- SAGE Asset Type Common Stock
- SAGE Market Capitalization 846.5M
- Earnings Per Share -8.39
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Are you looking to invest in the stock market from Malaysia, Thailand, Indonesia, or Vietnam? Look no further than SAGE Therapeutics. As a content marketing expert at Zorion, we understand the importance of making informed investment decisions. SAGE Therapeutics is a leading biopharmaceutical company focused on developing novel medicines for patients with life-altering central nervous system disorders. With a track record of groundbreaking research and a strong pipeline of potential therapies, SAGE Therapeutics presents an exciting investment opportunity. At Zorion, we offer investment insights and recommendations, along with access to educational materials, to help retail investors from these countries make well-informed decisions. Discover how to invest in the promising future of SAGE Therapeutics with Zorion.
